| Título: | Population Pharmacokinetic/Pharmacodynamic Analysis of the DPP-4 Inhibitor Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus |
| Autores: |
Tadayasu, Yusuke; Nippon Boehringer Ingelheim Co., Ltd.
Medical Development Div. Sarashina, Akiko Tsuda, Yasuhiro Tatami, Shinji Friedrich, Christian Retlich, Silke Staab, Alexander Takano, Mikihisa |
| Fecha: | 2013-12-17 |
| Publicador: | Journal of Pharmacy and Pharmaceutical Sciences |
| Fuente: |
 |
| Tipo: |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| Tema: | No aplica |
| Descripción: | [Objectives] Linagliptin is a novel, highly selective and long acting DPP-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM). Linagliptin exhibits non-linear pharmacokinetics (PK) due to saturable binding to plasma and tissue DPP-4. The aim of this study was to characterize the PK and PK/DPP-4 inhibition relationship of linagliptin in Japanese patients with T2DM using a population PK/DPP-4 model and to support the rationale for the therapeutic dose in Japanese patients by simulation. [Methods] Linagliptin plasma concentration and DPP-4 inhibition measurements from a placebo-controlled, parallel group multiple (28 days) dose trial that included 36 T2DM patients (18 patients each in 2.5 mg and 10 mg dose group) were used for analysis. Modeling was performed using FOCE INTERACTION estimation method implemented in NONMEM V. The linagliptin plasma concentration- and DPP-4 inhibition- time profiles were simulated for Japanese patients receiving 5 mg linagliptin once daily by the model established. [Results] Nonlinear PK of linagliptin in T2DM patients were well described by a 2-compartment model assuming concentration-dependent binding to DPP-4 in the central and peripheral compartment. Plasma DPP-4 inhibition was integrated in the model by relating the model-predicted DPP-4 occupancy with linagliptin linearly to DPP-4 inhibition. The simulation predicted that for the 5 mg dose group the trough DPP-4 inhibition at steady-state was 84.2%, which is higher than the target inhibition (≥80%) for an effective dose of DPP-4 inhibitor. In 2.5 mg dose group, steady-state DPP-4 inhibition of >80% was not maintained over 24 hours (observed and simulated). [Conclusions] The nonlinear PK of linagliptin and its plasma DPP-4 inhibition in patients were well characterized by a target-mediated drug disposition model relating DPP-4 occupancy with linagliptin to DPP-4 inhibition. Simulations of plasma DPP-4 inhibition suggest that 5 mg linagliptin once daily is an appropriate therapeutic dose for Japanese patients with T2DM.This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. |
| Idioma: | Inglés |
1 The Impact of Electronic Prescribing on the Professionalization of Community Pharmacists: A Qualitative Study of Pharmacists’ Perception por Motulsky, Aude; Université de Montréal,Winslade, Nancy; McGill University,Tamblyn, Robyn; McGill University,Sicotte, Claude; Université de Montréal | 6 Effect of Inflammation on Molecular Targets and Drug Transporters por Hanafy, Sherif; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada,El-Kadi, Ayman O.S.,Jamali, Fakhreddin; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada |
2 Statins Against Drug-Induced Nephrotoxicity por Dashti-Khavidaki, Simin; Tehran University of Medical Sciences,Moghaddas, Azadeh; Tehran University of Medical Sciences,,Heydari, Behrooz; Tehran University of Medical Sciences,,Khalili, Hossein; Tehran University of Medical Sciences,lessan-Pezeshki, Mahboob; Tehran University of Medical Sciences,,Lessan-Pezeshki, Mahbooh; Tehran University of Medical Sciences | 7 |
3 Hepatotoxic Botanicals - An Evidence-based Systematic Review por Abdualmjid, Reem J; University of Alberta,Sergi, Consolato; University of Alberta | 8 |
4 The Decrease in Farnesoid X Receptor, Pregnane X Receptor and Constitutive Androstane Receptor in the Liver after Intestinal Ischemia-Reperfusion por Ogura, Jiro,Terada, Yusuke,Tsujimoto, Takashi,Koizumi, Takahiro,Kuwayama, Kaori,Maruyama, Hajime,Fujikawa, Asuka,Takaya, Atsushi,Kobayashi, Masaki,Itagaki, Shirou,Takahashi, Natsuko,Hirano, Takeshi,Yamaguchi, Hiroaki,Iseki, Ken | 9 Functional Food and Nutraceutical Registration Processes in Japan and China: A Diffusion of Innovation Perspective por Patel, Darshika; University of Auckland,Dufour, Yvon; University of Auckland,Domigan, Neil; Auctus Limited |
5 HPLC Analysis of Mesembrine-Type Alkaloids in Sceletium Plant Material Used as An African Traditional Medicine por Patnala, Srinivas; Rhodes University,Kanfer, Isadore; Faculty of Pharmacy, Rhodes University | 10 Inhibition of Human Cytochrome P450 Metabolism by Blended Herbal Products and Vitamins por Tam, Teresa W; Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON,Akhtar, Humayoun; Guelph Food Research Centre, Agriculture and Agri-Food Canada, Guelph, ON,Arnason, John Thor; Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON,Cvijovic, Kosta; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON,Boon, Heather; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON,Cameron, D William; Faculty of Medicine, Univeristy of Ottawa, Ottawa, ON,Drouin, Cathy E; Centre for Research in Biopharmaceuticals and Biotechnology, University of Ottawa, Ottawa, ON,Jaeger, Walter; Department of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna,Tsuyuki, Ross T; Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB,Vohra, Sunita; CARE Program, Faculty of Medicine and School of Public Health, University of Alberta, Edmonton, AB,Foster, Brian C; Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa, ON |